Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

SOShane W. O’BrienALAshley LentoAHAllison Hartman

Discussion

Loading...

Member takes

Overview

Analysis reveals that momelotinib enhances anemia and splenomegaly management in myelofibrosis, suggesting effective drug combinations for treatment improvement.

Key Points

  • Momelotinib improved anemia and splenomegaly in myelofibrosis patients, highlighting key clinical benefits.
  • Combination screening identified inhibitors targeting signaling pathways, improving treatment outcomes.
  • Experiments utilized multiple isogenic cell line models to assess drug synergy and effects on malignant cells.
  • Discoveries may enable future therapeutic strategies for addressing the multifaceted nature of myelofibrosis.

Cite This Study

O’Brien et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfcdhttps://doi.org/10.1182/blood-2025-7279
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis2025
  2. 2Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study2025 · 2 citations
  3. 3Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.2025 · 2 citations
  4. 4Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination2025
  5. 5Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor2025